跳至主要内容
临床试验/NCT03092778
NCT03092778已完成不适用

Percutaneous Image Guided Cryoablation of the Vagus Nerve for Management of Mild-Moderate Obesity

Emory University6 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2017年6月13日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
6
主要终点
Number of Cryoablation Procedure Events (CPEs)

研究概览

简要总结

The purpose of this study is to assess the efficacy of cryoablation therapy for the treatment of mild to moderate obesity and test the safety (good and bad effects) of this procedure. The vagus nerve transmits hunger signals from the stomach to the brain, and in response transmits stomach expansion signals from the brain to the stomach. Investigators believe that by interrupting this communication, participants could experience less hunger and in turn lose weight.

详细描述

The purpose of this single arm study is to assess the efficacy of cryoablation therapy for the treatment of mild to moderate obesity and test the safety (good and bad effects) of this procedure. The vagus nerve transmits hunger signals from the stomach to the brain, and in response transmits stomach expansion signals from the brain to the stomach.Investigators believe that by interrupting this communication, participants could experience less hunger and in turn lose weight.

The rationale for using cryoablation to treat obesity is based on this investigator's experience safely targeting peripheral nerves via CT guidance and treated with thermal ablation in daily clinical practice. the primary objective of this research is to evaluate the feasibility and safety (over time) of percutaneous image guided cryoablation of the posterior vagus nerve in obese patients. The secondary objective consist of temporal evaluation of weight loss and appetite before and after the procedure. This will be analyzed through documentation of weight, and through the implementation of validated outcome instruments.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Body Mass Index (BMI) 30-35
  • Weight loss refractory to diet changes or exercise
  • Absence of coagulopathy
  • Ability and willingness of patient to provide written informed consent

排除标准

  • Active infection
  • Underlying congenital anatomic or other spinal anomalies that result in non-conventional anatomy at the gastro-esophageal junction
  • Pregnant or planning to become pregnant
  • Immunosuppression
  • History or laboratory results indicative of any significant cardiac, endocrine, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neoplastic, or other disorder that in the opinion of the Principal Investigator would preclude the safe performance of cryoablation
  • Uncorrectable coagulopathies
  • Concurrent participation in another investigational trial involving systemic administration of agents or within the previous 30 days
  • Have undergone a previous bariatric surgical intervention

研究组 & 干预措施

Cryoablation Group

Experimental

Participants with mild to moderate obesity will undergo a cryoablation procedure to the vagal nerve.

干预措施: Cryoablation (Procedure)

结局指标

主要结局

Number of Cryoablation Procedure Events (CPEs)

时间窗: Post Intervention (Up to 24 Hours)

Adverse events which occur within the first 24 hours following cryoablation.

Frequency of Breakthrough Events

时间窗: Duration of Study (Up to 2 Years)

The frequency of events requiring emergency or urgent physician consultation.

Number of Breakthrough Events

时间窗: Duration of Study (Up to 2 Years)

The number of events requiring emergency or urgent physician consultation.

Number of Adverse Events

时间窗: Duration of Study (Up to 2 Years)

Clinical signs or symptoms of infection (fever), hemorrhage (pain, imaging changes), that occur outside of the time periods specified for CPEs.

Number of Significant Adverse Events (SAEs)

时间窗: Duration of Study (Up to 2 Years)

Significant adverse events include life-threatening adverse events and death.

次要结局

  • Recruitment Rate(Duration of Study (Up to 2 Years))
  • Weight(Baseline, Month 6 (Post Intervention))
  • Hip Circumference(Baseline, Month 6 (Post Intervention))
  • Food Frequency Questionnaire (FFQ)(Week 1, Month 6 (Post Intervention))
  • Number of Candidates who Chose not to Participate(Duration of Study (Up to 2 Years))
  • Withdrawal Rate(Duration of Study (Up to 2 Years))
  • Retention Rate(Duration of Study (Up to 2 Years))
  • Body Mass Index (BMI)(Baseline, Month 6 (Post Intervention))
  • Kaiser Physical Activity Survey (KPAS)(Week 1, Month 6 (Post Intervention))
  • Enrollment Rate(Duration of Study (Up to 2 Years))
  • Height(Baseline, Month 6 (Post Intervention))
  • Moorehead-Ardelt Quality of Life Questionnaire(Week 1, Month 6 (Post Intervention))
  • Exclusion Rate(Duration of Study (Up to 2 Years))
  • Protocol Deviation Rate(Duration of Study (Up to 2 Years))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

John Prologo

Assistant Professor

Emory University

研究点 (6)

Loading locations...

相似试验